Read on Twitter
As a prescribing pharmacist providing care to oncology patients, it is very clear that @AmerMedicalAssn remains largely unaware of the role of prescribing #pharmacists. Here is a short 
... 1/x https://twitter.com/AmerMedicalAssn/status/1322342527287070722
... 1/x https://twitter.com/AmerMedicalAssn/status/1322342527287070722
Prescribing clinical pharmacists provide distinct (not duplicative) care to patients. Oncologists have a significant burden making accurate diagnosis & making treatment decisions. Clinical pharmacists are part of the execution team to ensure the treatment is **optimized** 2/x
We ensure patients have proper prophylactic medications (antiemetics, antibiotics, GCSF, etc) and prescribe the necessary medications to manage toxicities so that patients are able to stay on their chemotherapy and maintain dose intensity. 3/x
Practically speaking, prescribing pharmacists are an asset to clinical practice, allowing for more efficient patient care. We have collaborative practice agreements with certification from boards of pharmacy and medicine (here in NC). 4/x
And the data are clear. Our work has shown that this collaboration 1) helps pts by improving symptoms, improving adherence, and improving outcomes & 2) MDs are satisfied with this service because it allows them to focus on other aspects of pt care. https://pubmed.ncbi.nlm.nih.gov/29799768/ 5/x
So if prescribing #pharmacists benefit patients AND physicians are satisfied, I argue @AmerMedicalAssn should follow the data and support this collaborative care. To quote @LarryBuie "every patient *deserves* a #pharmacist in their care." 6/x
Lastly, reminder that #pharmacists provide pt care--and improve clinical outcomes--without getting properly reimbursed. So, instead of being divisive, let's #FollowTheData and support #ProviderStatus for #pharmacists. THAT is what our patients deserve. 7/7 (done)
